“a nonsignificant trend”

Patients with features of PVOD demonstrated a nonsignificant trend for worse survival free of lung transplantation (median survival of 66.2 versus 105.3 months; IQR 64.2–68.2 versus 64.5–199.4; p=0.258).

Additionally, hemodynamic instability showed a nonsignificant trend toward higher occurrence in the intervention group compared with the control group ( P = 0.259)( Table 3 ).

Dogs with proteinuria of UPC >1, there was a nonsignificant trend ( P = .26) in the frequency of hypoalbuminemia between quartiles; Q1 12.5%, Q2 21%, Q3 24%, Q4 33%.

Similarly, none of the calculated indexes was affected by Dmab ( Table 2 ), though HOMA-IR and insulinogenic indexes showed a trend toward reduction (2.01 ± 1.52 versus 1.81 ± 1.05; p =0.27 and 0.78 ± 0.64 versus 0.64 ± 0.48; p =0.45, respectively), while Matsuda and QUICKI Indexes showed a nonsignificant trend to increase (5.79 ± 3.51 versus 7.64 ± 8.58; p =0.26 and 0.362 ± 0.043 versus 0.365 ± 0.042; p =0.51, respectively).

In addition, a nonsignificant trend of higher semen volume (3.9 vs. 3.4–3.5 ml; P = 2.60 × 10 −1 ) but lower sperm concentration (42 vs. 63 million/ml; P = 1.27 × 10 −1 ) and total sperm count per ejaculate (162 million vs. 220 million; P = 5.46 × 10 −1 ) was observed among TT subjects.

Those with insufficient vitamin D levels (20–30 ng/mL) showed a nonsignificant trend toward higher odds of hypocalcemia (OR = 2.00, 95% CI 0.66–6.71; p = 0.26) and hypothyroidism (OR = 1.65, 95% CI 0.66–4.14; p = 0.28).

Additional lesions sets as a whole were associated with a nonsignificant trend toward worse outcomes (−5.3% change in freedom from atrial arrhythmia 95% CI, −13.8% to 3.1%; P =0.26).

Prognostic Impact of MGMT Silencing in PAC MGMT ‐methylated PAC patients had a nonsignificant trend toward longer overall survival (OS, 21.7 vs. 19.5 months, HR 0.72 [95%CI 0.39–1.32], Wald test p = 0.26), which was confirmed using MGMT expression values (as a continuous variable) in a univariable and multivariable analysis (Figure 3a,b and Figure S9a,b ). 3.6.

normoxia, P < 0.001), while there was a nonsignificant trend for CO 2 clamping to exert a greater effect on exercise time in hypoxia compared to normoxia (CO 2 : P = 0.262, interaction: P = 0.097).

8.1% in moderate ePWV and 7.4% in high ePWV, p = 0.020) and a nonsignificant trend toward higher diastolic dipper status (56.7% vs. 40.1% and 45.4%, respectively, p = 0.263) (Table 2 ). 3.4.

There was a nonsignificant trend towards higher prevalence of renal dysfunction (4.5%, n = 4 vs. 9.3%, n = 10) ( P = 0.268), metabolic (4.5%, n = 4 vs. 10.3%, n = 11) ( P = 0.179) and psychiatric disorders (12.5%, n = 11 vs. 19.6%, n = 21) ( P = 0.244) in patients with high BVL.

As displayed in Figure 4 , panel D, liberals adopted more postmodernist attitudes when conservatives were portrayed as open‐minded ( b = −0.48, p = 0.007), and conservatives showed a nonsignificant trend in the opposite direction ( b = 0.21, p = 0.269).

Compared with the control group, participants in “app frequent” showed a nonsignificant trend toward higher odds of successful completion of MTA (aOR 1.462, 95% CI 0.745–2.869; p = 0.2693), whereas “app seldom” had markedly lower odds (aOR 0.124, 95% CI 0.024–0.645; p = 0.0131).

Thus, individuals who had this reaction after their first dose and received the second injection in the same arm as their first had 2.10 times the risk (95% CI: .53 to 8.29) of another delayed reaction compared with those who received the second injection in the opposite arm, a nonsignificant trend ( P = .2763).

There was a nonsignificant trend to more frequent emergence of new protease resistance mutations in subtype B (18%) vs. subtype C (8%, P =0.277) or non-B (7%, P =0.088) subjects; however, subtype B subjects were more likely to have previously been treated with PIs.

When evaluating the latency between the first time pain, distress, depressive symptoms, neglect, or abuse were documented in the chart and PC referral, there was a nonsignificant trend toward shorter latency in HGG patients (45.5 ± 76.6 weeks) compared with non‐CNS cancer patients (75.8 ± 129 weeks, p = 0.277).

In patients undergoing hemodialysis, a nonsignificant trend toward reduced mortality was observed (aHR, 0.72; 95% CI, 0.39-1.31; p = 0.277), possibly due to limited sample size.

A subanalysis of only patients with positive culture results (n = 52) demonstrated a nonsignificant trend toward lower WBC count and percentage of PMNs among patients who received antibiotics before aspiration ( P = .28) ( Table 3 ).

A post hoc analysis of the MI events in the LEADER trial showed a nonsignificant trend toward less CV death due to MI events in patients taking liraglutide versus placebo (4.7 vs. 6.7%, P = 0.28) ( 46 ).

They hypothesized that BAPN administration could improve AVF patency and found that local delivery of BAPN in rat AVFs through an electrospun scaffold significantly decreased wall fibrosis (34.79 ± 3.83 versus 47.17 ± 8.65%; p = 0.03) and demonstrated a nonsignificant trend toward increased blood flow (34.03 ± 17.32 versus 24.80 ± 7.60 mL/min; p = 0.28) versus vehicle-loaded scaffolds at day 21 [ 58 ].

In MM, CEACAM1 expression was not significantly associated with recurrent cytogenetic abnormalities, although a nonsignificant trend toward higher expression in t(11;14) cases (75% vs 53%, Fisher exact P = .28).

Meta-analysis showed a nonsignificant trend for reduction in systolic blood pressure between the experimental group and the control group [WMD = –1.02, 95% CI(–2.88, 0.84), P = 0.281] ( Figure S12 ). 3.4.9.

There was a nonsignificant trend toward the predominance of females among AZD1222 vaccinated patients ( P = 0.282).

In the case of IL-5 and IL-10, 15% (11/73) and 16.4% (12/73) of patients diagnosed <10 years ago responded, respectively, while only 4.3% (1/23) of those diagnosed >10 years ago responded, which corresponded to a nonsignificant trend ( p = 0.283 and 0.179) in the same direction as observed for IFNγ.

In total, PFS of TP53 co-mutated patients was 3.9 months [ n = 60 (95% CI: 2.4–5.6)] and 10.3 months in TP53 wt patients [ n = 168 (95% CI: 8.6–12.0)] regardless of treatment ( P < 0.001) (Figure 3 A and supplementary Table S2 , available at Annals of Oncology online). The ALK variant 3a/b subgroup (cohorts A–D, n = 20) showed a nonsignificant trend toward better PFS with 11.9 months (95% CI: 0.9–23.1) versus variant 1 ( n = 31) with 7.9 months (95% CI: 1.6–14.4) ( P = 0.285).